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Abstract 
The University of Minnesota Social and Administrative Pharmacy Program proposed Guidelines for Formulary Evaluations (GFE) are 
designed to focus on the credibility of clinical and cost-outcomes claims in formulary decision making. The last few years have 
witnessed increasing concern over the credibility of trial based efficacy claims, with a surprisingly high proportion of claims falling 
short. At the same time cost-outcomes claims, where comparative clinical claims are a key input, have been presented where the 
claims made are not open to experimental or observational assessment. This follows from standards recommended for modeled and 
simulated claims. In the absence of cost-outcomes claims being presented in an evaluable form, it is impossible not only to replicate 
the claim or to judge whether or not it is credible. Claims for product value based on such claims are unacceptable.  The guidelines 
proposed here are designed to overcome these limitations and support an evidence base that is both credible and replicable for 
formulary decisions. This is achieved by focusing on short-term modeled or simulated claims for cost-effectiveness. The requirement 
for modeled or simulated claims that are evaluable within a time frame that is meaningful for formulary decisions marks a major 
departure from format submissions already in play, not only in the US but in other developed economies. Rather than subscribing to 
the gold standard of long term or lifetime cost-per-QALY claims a short-term time horizon of no more than 2-years is recommended. 
This allows products to be provisionally placed on formulary but subject to a protocol that supports an evaluation to be reported back 
to a formulary committee as part of ongoing disease area or therapeutic class reviews. The place of the product and its contracted 
price can then be reviewed. 
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Introduction 
Over the past 25 years increasing attention has been given to 
standardizing modeled or simulated claims for the 
comparative clinical and cost-effectiveness claims for 
pharmaceutical products. The result has been the publication 
of literally hundreds of modeled or simulated claims, together 
with submissions to formulary committees. Unfortunately, in 
the overwhelming majority of instances the modeled claim 
has failed to meet the standards of normal science: claims 
have been presented that are either untestable or presented 
in untestable terms 1 2. This is seen most obviously in claims 
presented for chronic disease interventions where the  
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modeled outcomes are in long-term or lifetime cost-per-QALY 
terms. On the standards of normal science such claims should 
either be rejected or, if possible, recast in a form that allows 
them to be evaluated experimentally or observationally. 
 
This fundamental methodological flaw has characterized, not 
only the various versions of the Academy of Managed Care 
Pharmacy (AMCP) Format for Formulary Submissions in the 
US but also those exemplar formulary submission guidelines 
including the National Institute for Health and Care 
Excellence (NICE) in the UK, the Pharmacy Benefits Advisory 
Committee (PBAC) in Australia and the Canadian Agency for 
Drugs and Technologies in Health (CADTH) 3  4  5  6. The 
problem is that none of these guidelines, including the latest 
version 4 of the AMCP Format for Formulary Submissions 
published in April 2016 meet the standards for ‘normal 
science’: they support the construction of modeled claims for 
clinical and cost-effectiveness that fail to generate testable 
and reproducible hypotheses (or claims) for the anticipated 
impact of products in health care systems. As such, they are 
best considered as imaginary worlds or thought experiments.  
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The recipient of the submission has no idea of whether the 
claims made are right or even if they are wrong. While the 
author(s) of the modeled claims may justify their construct on 
the grounds that it reflects their perception of reality, the 
claims have the potential to be misleading, even harmful, in 
supporting formulary decisions but to an unknown and 
unknowable extent. 
 
The requirement for testable hypotheses in the evaluation 
and provisional acceptance of claims made for products and 
devices is unexceptional. Since the 17th century it has been 
accepted that if a research agenda is to advance, if there is to 
be an accretion of knowledge, there has to be a process of 
discovering new facts. Indeed, as early as the 16th century 
Leonardo da Vinci (1452 – 1519) in notes prepared 
posthumously in 1540 for his Treatise on Painting (published 
in 1641) clearly anticipated the standards for the scientific 
method which were widely embraced a century later in 
rejecting thought experiments that fail the test of experience. 
By the 1660s, the scientific method, following the seminal 
contributions of Bacon, Galileo, Descartes, Huygens and 
Boyle, had been clearly articulated by associations such as the 
Academia del Cimento in Florence (1657) and the Royal 
Society in England (founded 1660; Royal Charter 1662) with 
their respective mottos Provando e Riprovando (prove and 
again prove) and nullius in verba (take no man’s word for it).  
 
In the early 20th century standards for empirical assessment 
were put on a sound methodological basis by Popper in his 
advocacy of a process of ‘conjecture and refutation’ and the 
demarcation of science from nonscience 7 8.  Hypotheses or 
claims must be capable of falsification; indeed they should be 
framed in such a way that makes falsification likely. Life 
becomes more interesting if claims are falsified because this 
forces us to reconsider our models and the assumptions built 
into those models. This leads, then, to the obvious point that 
claims or models should not be judged on the realism or 
reasonableness of their assumptions or on whether the 
model ‘represents’ reality. It is worth reflecting on Popper’s 
comment on induction: ‘never in science are inferences 
drawn from mere observational experience to the prediction 
of future events’ 9. Or, to put it simply: not all swans are 
white. 
 
If we accept the standards of normal science then it is 
possible to make a distinction between science and 
pseudoscience. As Pigliucci points out, while the designation 
‘science’ captures a range of disciplines ranging from the 
‘hard’ sciences of controlled experiments to the more ‘soft’ 
sciences of non-laboratory assessments, the three core 
elements of science that characterize and link these 
disciplines are: (i) it is an investigation of nature; (ii) it is 
committed to the construction of empirically verifiable 
theories; and (iii) it is further committed to testing through 
observation or experimentation 10. Failure to meet these core 
elements, notably the ability or commitment to ‘produce and 
test hypotheses based on systematically collected empirical 
data [via experiment or observation]’ is what differentiates 
science from non-science or pseudoscience. These 
boundaries are not hard and fast. A field can fall into the 
pseudoscience category yet practitioners may not see this as 
a problem even though they refuse to accept the testability 
criterion. 
 
Outcomes Based Formulary 
It is not as though the issue of testable claims has not been 
raised before in submissions to formulary committees. This 
dichotomy between predictive validation and claims that a 
model is ‘realistic’ and that its claims should be taken at face 
value were recognized some 10 years ago in the WellPoint 
formulary submission guidelines in their focus on an 
outcomes based formulary 11 12. The guidelines, first issued in 
2005, were explicit as to the need for predictive claims as an 
input to regular and ongoing disease area and therapeutic 
class reviews. The guidelines were designed to set standards 
for new product submissions as well as submissions to 
support disease area and therapeutic class reviews. A 
requirement in new submissions was that claims for costs and 
outcomes should be in a form that allowed validation in the 
short term. Those making a submission were asked to submit 
a protocol that detailed how these claims were to be 
assessed and reported back to the formulary committee. In 
the context of a life cycle perspective on drug products, initial 
claims were seen as provisional and subject to ongoing 
reviews to capture the impact of new products through 
comparative assessments. Claims that could not be verified 
were to be rejected or put to one side, to include non-
testable modeled claims and simulations. 
 
More recently, in a supplement to the Journal of Medical 
Economics, the case was put forward that if claims for the 
impact of products and devices on costs and outcomes in 
health care systems are to be accepted then they should 
meet the standards expected in ‘normal science’  13  14  15  16  17. 
The only acceptable modeled claims in formulary submissions 
are those that are testable in a timeframe relevant to the 
needs of a formulary committee. If claims do not meet this 
standard they should be rejected or recast in an acceptable 
format. The supplement, given the experience of modeled 
claims made to NICE and the current situation in the US and 
other developed economies, proposed a new research 
agenda that focused on the testable impact of products and 
devices on patient outcomes, resource utilization and the 
costs of health care delivery. Key elements in this proposed 
new research agenda were that formulary submissions claims 
should be evaluated and reported on in a timeframe that is 
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meaningful to the committee. In practice, this would mean 2-
3 years with results reported on as part of ongoing disease 
area and therapeutic reviews. To support this process the 
supplement recommends that formulary submissions be 
accompanied by a protocol detailing how the claims are to be 
evaluated and a short list of questions a formulary committee 
should ask of a manufacturer’s submission. At the same time 
the supplement points to the ready availability of ‘big data’ to 
support claims evaluation. 
 
The fundamental point is that models or simulations can fail 
irrespective of claims made that if the simulation is sufficient 
in its correspondence to reality then it necessarily entails the 
claims made. The fact is that it is entirely possible to 
construct competing simulations that come to diametrically 
opposed conclusions 18. Unless claims are presented as 
evaluable hypotheses there is no experimental basis for 
judging the worth of a simulated claim let alone the merits of 
competing claims. 
 
The purpose of the Guidelines for Formulary Evaluation (GFE) 
proposed here is to argue that the present standards for 
formulary submissions should be put to one side 19. Current 
standards, as exemplified in the US with the latest version 4 
of the AMCP Format for Formulary Submissions, fail to meet 
the standards of normal science. Their emphasis on the 
construction of evidence through modeled and simulated 
claims lacks credibility. There is no commitment to produce 
and test hypotheses. Rather, as detailed in the GFE, the focus 
should be on submissions that support short-term evaluable 
modeled or simulated claims; claims that can be evaluated 
within a relatively short time frame and reported back to 
formulary committees as part of ongoing disease area and 
therapeutic class reviews. 
 
Credibility and Replication 
The need to set new standards for formulary submissions and 
evaluations is, if we accept the importance of subscribing to 
the standards of normal science, long overdue. There is now 
increasing concern regarding the limited and, in many cases, 
dubious evidence base that has supported formulary 
decisions. This has stemmed, in part, from the inability to 
replicate results reported for pivotal clinical trials 20  21. At the 
same time, there are well documented instances of outcomes 
switching where the primary and secondary outcomes claims 
presented to support formulary listing are inconsistent with 
the primary and secondary outcomes initially proposed in the 
original phase 3 protocols 22. The re-configuration of 
outcomes claims and the absence of replication both impact 
the credibility of clinical claims. 
 
If doubt is expressed as to the credibility of individual clinical 
claims, then further doubts are raised if disparate clinical 
claims are bundled together and re-calibrated to generate 
indirect comparisons for comparative efficacy for classes of 
competing therapies. 
 
If, to take a further step, these indirect claims are a key input 
to modeled or simulated cost-effectiveness claims, credibility 
is further lessened if claims for cost-effectiveness are 
presented in a form that prohibits experimentation. In this 
case, we are not even at first base: there is no way in which 
these cost-effectiveness claims can be evaluated let alone 
replicated. 
 
The absence of evaluable claims places a formulary 
committee in a difficult situation; (i) they can take the non-
evaluable claims on board on the basis that some evidence 
(even if we can’t judge its merits) is better than none; (ii) they 
can take it on board on the grounds that it represents the 
professionally agreed standard for modeled or simulated yet 
untestable claims by groups such as the International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR) and 
agencies such as the AMCP and NICE; or (iii) they can reject 
the claim on the grounds that it is purely speculative and 
lacks any credibility 23  24. They might also add that, under (i) 
and (ii) acceptance of a modeled or simulated claim lays them 
open to challenge if they are asked to justify a formulary 
placement and pricing decision. 
 
The purpose of the GFE is to support option (iii). To ensure 
that claims supporting formulary decisions are credible. 
Manufacturers and others who submit claims are asked to 
justify the claims made by presenting those claims in an 
evaluable form, supported by an assessment protocol. All 
claims made for products should be treated as provisional. 
The decision then rests with the formulary committee either 
to provisionally accept a product subject to the claims being 
evaluated and reported back to the committee or to put 
formulary review to one side until a claims assessment has 
been presented. If an assessment has already been made 
then these results can be reported to the committee as part 
of the submission.  
 
Quality and Affordability of Care 
Requiring claims for products to be evaluable is essential if 
clinical and pricing decisions are to be driven by a credible 
evidence base. Feedback is essential if the credibility of claims 
is to be maintained. This does not mean evidence from one or 
more phase 3 trials, but evidence from assessing those claims 
in the target patient population. The guidelines proposed are 
designed to support value and care co-ordination initiatives in 
the delivery of health care to target populations. Consistent 
with the objectives of the Patient Protection and Affordable 
Care Act the guidelines are designed to support quality 
outcomes and metrics in health care delivery 25. The 
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guidelines provide a basis for a credible, robust and replicable 
evidence base in formulary decisions. If such an evidence 
base is in place then it can usefully support a shift to 
population-based value payment systems that focus on not 
just personalized but precision medicine in matching 
individuals to products. 
 
Evaluating Formulary Submissions 
The first part of the GFE is concerned with the credibility and 
replication of clinical claims for the product and its 
comparators. All submissions are by invitation from the 
formulary committee or the health system. Manufacturers 
and others making a submission are asked, in the first place, 
to provide a full description of the product and its 
comparators (with respective product inserts). This should be 
accompanied by a comparative clinical assessment, reporting 
both direct and indirect comparisons between the product 
and comparator therapies.   
 
For each product and comparators the target populations 
(including potential sub-populations) should be identified and 
profiled. This description should include an epidemiological 
profile together with a demographic and clinical profile; the 
latter to detail co-morbidities.  In addition, with the 
increasing emphasis on personalized or precision medicine, 
target populations may further be described in terms of their 
molecular taxonomy or pathology. If this is a consideration, 
the molecular algorithm should be detailed together with the 
choice of diagnostic or test device. The place of the product 
and comparators in therapy should be described together 
with treatment guidelines supporting product placement.  
 
With increasing concern being expressed over the pricing of 
drugs, for example in the anticancer area for end-of-life 
metastatic treatments, a critical input to a formulary decision 
is the launch price (wholesale acquisition cost) of a product 
and the current price of comparator therapies for the target 
indications.  The GFE asks manufacturers to indicate what the 
anticipated launch price of the drug is expected to be (or the 
current price if it has already been launched).  Where a drug 
has been launched, information should be provided on 
whether or not there have been price changes since launch.  
At the same time, for comparison purposes, manufacturers 
are asked to provide anticipated launch or current prices in 
other global markets: Canada, the European Union and 
Australia. 
 
A particular emphasis is placed on the credibility of product 
and comparator claims. Those making the submission are 
asked to detail (and provide summary protocols) regarding 
the original primary and secondary outcomes that the pivotal 
phase 3 trials were intended to address. Respondents are 
then asked to detail (i) if there have been any amendments to 
the original trial protocol resulting in outcomes switching and 
(ii) whether the published claims are consistent with the 
initial trial protocol. Any discrepancies are to be noted. In 
addition, in respect of the claims made, respondents are 
asked whether there have been any attempts to replicate 
published claims for both primary and secondary outcomes 
and whether the claims have been supported. This 
requirement applies to both the product and comparators. In 
addition, if indirect comparative outcome claims have been 
presented as part of the submission, the respondent is asked 
whether or not these have been evaluated and replicated. 
 
The respondent is also asked to detail the incidence of 
significant adverse events for both the product and 
comparators for (i) the pivotal phase 3 trials and (ii) the post-
market entry period. Where there has been a reported 
replication of the primary and secondary claims, the adverse 
profile should be reported and matched against those 
reported for the pivotal trials. 
 
Finally, the respondent is asked to address the issues of 
adherence and persistence to the index prescription for the 
product and comparators. For each of the product and 
comparators evidence is required for adherence and 
persistence behavior (i) during the pivotal phase 3 trials and 
(ii) for a period up to 4 years from product launch. In the 
latter case the evaluation should include evidence for 
switching between the product and comparators as well as 
between the comparator products. This review of adherence 
and persistence should report on descriptive studies as well 
as those that have attempted to assess the determinants of 
this behavior in the therapeutic product class.  The review 
should report on the extent to which patterns of adherence 
and persistence have modified primary clinical claims for the 
product and comparators in the target population or sub-
populations, together with the results of any interventions to 
impact adherence and persistence behavior.      
 
Cost-Outcomes Claims 
The issues of credibility and replication apply equally to cost-
outcomes claims as they do to clinical claims. In the second 
part of the GFE it is proposed that cost-outcomes claims 
should only be considered credible (and acceptable) if:  (i) the 
claims are evaluable; and (ii) the proposed claims evaluation 
provides feedback in a meaningful time horizon. Modeled or 
simulated claims that fail to meet these criteria could be 
recast in evaluable terms or simply rejected. These would 
include claims that profess to capture the natural course of a 
disease, employing Markov or discreet event techniques. 
These are of no interest if they generate untestable claims for 
long-term or lifetime cost-per-QALY outcomes.  
There is no restriction on the type of cost-outcomes claims 
that can be submitted. Outcomes can be expressed in clinical 
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terms or as patient reported outcomes (PROs). The GFE does 
not encourage claims expressed as QALYs. It needs to be 
demonstrated that QALY and cost-per-QALY claims are a 
unique feature of the intervention that should be captured 
and reported in a meaningful time frame. Otherwise, QALY 
claims should be put to one side. 
 
Where patient reported outcomes are used they should meet 
accepted standards for their measurement properties with a 
statement indicating whether or not interval differences are 
clinically meaningful.  
 
The critical issue is the modeled time frame. As a rule of 
thumb, a model time-horizon that extends beyond 2 years is 
unlikely to be acceptable. Long-term or lifetime simulated 
cost-outcomes claims are considered irrelevant, and 
potentially misleading, for formulary decisions. 
 
From an evaluation perspective, it is important that claims 
made are capable of being assessed either from existing data 
sets (e.g., administrative claims linked to EMRs) to capture 
resource utilization impacts as well as clinical endpoints or 
from a prospective observational study to capture outcome 
such as generic utilities that are not typically captured in 
EMRs. Those making the submission have the choice, 
therefore, of tailoring their claims to available data from third 
party vendors or underwriting a prospective study. 
Whether the modeled or simulated claims are presented as 
outcomes from a simple decision model or as a more complex 
structure such as a Markov model or a discrete event 
simulation is at the discretion of those preparing the 
submission. Similarly, it is at the discretion of those preparing 
the submission whether they present claims as incremental 
cost-outcomes ratios with supporting sensitivity analyses and 
probabilistic claims. The focus is on the claims being 
presented in evaluable terms. 
 
Again, it is also entirely at the discretion of those making the 
submission whether they want to support their choice of 
model and the assumptions driving the model by reference to 
quality checklists such as CHEERS 26. The focus on generating 
testable predictions means that a model is not judged on the 
correspondence of its input assumptions and core 
mechanism to some perception of reality. The issue of the 
sufficiency of correspondence to the real world necessarily 
entailing the claims made is irrelevant. The merits of a model 
rest upon its ability to generate testable claims and the 
results of the assessment of those claims. 
 
Modeled claims should accommodate anticipated adherence 
and persistence behavior. In many chronic disease states 
product utilization data point to relatively low rates of 
adherence and persistence by the end of the first 12 months 
from the index prescription. Those presenting a submission 
should make clear what the anticipated adherence and 
persistence behavior for the product is expected to be and 
whether or not it offers advantages over comparator 
products. Modeled claims should not be based on a possible 
minority of patients introduced to a new therapy who are 
assumed to be adherent (e.g., medical possession ratio ≥ 0.8) 
and persistent over a modeled time horizon of, say, 2 years. 
 
In situations where a manufacturer has already submitted a 
protocol elsewhere and is underwriting an evaluation this 
should be reported as part of the submission. In this case, as 
long as the formulary committee agrees that the protocol is 
acceptable, then the manufacturer should commit to 
reporting to the committee once the other study is complete. 
There is no requirement for any evaluation to be undertaken 
in the health system’s patient population.  
 
Finally, it is not the intention of GFE to support modeled cost-
utility claims that are designed to demonstrate that a product 
or device is ‘cost-effective’ because it generates incremental 
claims that are below a notional community willingness to 
pay threshold. If a formulary committee is prepared to base 
its decision making on willingness to pay thresholds that is 
their decision and they should inform those making 
submissions accordingly.  
 
Claims Assessment Protocol 
The claims assessment protocol proposed in the final section 
of the GFE is the critical link between the claims presented as 
a result of models or simulations and the subsequent 
assessment of those claims. The format for a protocol 
submission, which follows from an earlier protocol standard 
(PROST), is detailed in Table 1.  
 
The GFE protocol format applies to both retrospective and 
prospective studies where patients are tracked from existing 
data sources as well as to prospective observational studies 
(including randomized trials) that involve reporting from 
human subjects.  
 
On submission, the protocol is reviewed by the formulary 
committee. The questions the formulary committee should 
address are detailed in Table 2 under six subject areas: the 
objectives of the proposed study; the context; the target 
population; the claims to be evaluated; the study design and 
study implementation and reporting. 
 
Discussion 
The primary purpose of the GFE is to move the focus of 
attention in formulary evaluations to standards that are 
consistent with the scientific method: an acceptance of 
experimentation and the discovery of new facts in clinical and 
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cost-effectiveness claims. A shift in focus from an acceptance 
that constructed evidence driven by models and simulations 
generating untestable claims is the cornerstone of formulary 
decision making. This shift in focus does not put aside 
decision modeling or Markov and discreet event simulation 
constructs. Rather, it asks that these techniques support 
short-term evaluable modeled claims that can be assessed 
and the outcomes reported back to formulary decision 
makers in a meaningful time frame. A requirement that is not 
found in the AMCP Format for Formulary Submissions. 
 
The issue is one of credibility. Formulary decisions should be 
evidence driven, transparent and replicable. If clinical claims 
based on pivotal phase 3 trials show an unfortunate tendency 
toward non-replicability then claims for comparative cost-
effectiveness, which rely upon those same clinical claims as a 
major input to models or simulations, are in an even more 
precarious position. Unlike phase 3 claims, where replication 
is protocol driven, the absence of testable claims from cost-
effectiveness models and simulations fail even to get to first 
base: there are no testable claims to evaluate, let alone 
replicate. 
 
Over the past 25 years literally hundreds if not thousands of 
modeled cost-effectiveness claims have been presented and 
accepted as inputs to formulary decisions. The fact that these 
typically put forward untestable claims points to a possible 
alternative explanation for this apparent rejection of the 
scientific method. The emphasis on models and simulations 
may represent an acceptance, whether fully articulated or 
not, of the relativist or equivalence program in science 27. This 
‘strong program’ argues that the content of science is 
explained sociologically. It rejects the notion of superior 
evidence in favor of the belief that evidence is never 
discovered, it is constructed within a particular social 
community.  No one body of evidence is superior to another. 
The success of a research program is judged by its ability to 
receive the support of that particular community. Truth is 
consensus. Science is about ‘rhetoric, persuasion and 
authority’. Indeed, a relativist, if we accept this 
interpretation, may see the fact of a model’s untestableness 
as the characteristic that makes them so valuable, if not 
essential, to making the best possible policy and clinical care 
decisions. Modeling, in this belief system, is seen as filling 
gaps left behind after other forms of evidence have been 
exhausted, thus  providing essential value. 
 
Judged by the standards of normal science, the relativist 
position is unacceptable and best characterized as 
pseudoscience. In the absence of experimentation we have 
no idea whether the claims for clinical benefit or cost-
effectiveness are right or even if they are wrong. The fact that 
the author of an ‘untestable’ simulation believes the 
correspondence of the model to reality is sufficient and that 
the claims are necessarily entailed is no defense. It puts to 
one side any notion of progress, the discovery of new facts. It 
is this commitment to experimentation and observation that 
underpins these proposed standards for formulary 
evaluation. If this is unacceptable then it is difficult to see 
how we can continue to justify the creation and publication 
of untestable modeled or simulated cost-effectiveness claims 
without, in the near future, someone pointing out that the 
emperor has no clothes. 
 
Conclusions 
The standards for product evaluation proposed here mark a 
significant departure from accepted standards for formulary 
submissions and recommended standards for the modeling 
and validation of claims. The reason for this is quite simple: 
current standards lack credibility. Their acceptance by 
manufacturers, academic groups, professional associations 
and recipients of modeled claims is beside the point. After all, 
it took the best part of 1500 years to overthrow the 
straightjacket of Aristotelian philosophy. Judged by the 
criteria of normal science, the acceptance of the scientific 
method, current standards fail to support the process of 
‘systematic observation, measurement, and experiment, and 
the formulation, testing, and modification of hypotheses’ 
(OED) 28. To the contrary, the standards currently in place 
suggest an alternative interpretation: a relativist position that 
rejects any appeal to superior evidence. Science, in this view, 
is not a way of coming to grips with reality. Evidence is never 
discovered, it is always ‘constructed’. Truth is consensus. In 
contrast, the standards proposed here for formulary 
evaluations clearly reject a relativist position. GFE offers a 
practical guide to formulary evaluations. With a commitment 
to the standards of normal science, formulary decisions can 
rest on a credible evidence base. An evidence base that 
recognizes the need for replication of claims, the 
fundamental importance of experimentation and 
observation, and the discovery of new facts to ensure value in 
the delivery of health care. 
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Table 1: GFE Protocol Submission Format 
Section Required Content 
Title Proposed Assessment Protocol for Evaluating Clinical and Cost-Outcome Claims for [product] 
Abstract Structured summary of protocol assessment objectives: (i) claims to be evaluated; (ii) target 
population; (iii) proposed study design; (iv) data sources; (v) timelines for evaluation; and (vi) 
reporting standard 
Context A statement of the context of the study to include: (i) a systematic review of clinical and 
modeled cost-effectiveness claims for the product and comparators in the relevant time 
horizon; (ii) a systematic review of adherence and persistence patterns for the product and 
comparators in the target population; and (iii) a statement of the contribution this study is 
expected to make in evaluating competing interventions in this disease or therapy area. 
Claims A statement of the claims that the proposed study will be evaluating: (i) clinical outcomes; (ii) 
adverse event and safety outcomes; (iii) resource utilization outcomes; (iv) direct medical costs; 
and (v) cost-effectiveness. 
Target 
Population 
Characteristics of target population (age, gender, ethnicity, race) to include sub-groups and 
clinical markers (presence/exclusion of co-morbidities; stage of disease) 
Data Description of proposed data source(s) and any permissions required to access data/target 
population (e.g., IRB approvals, EMR approvals, access to administrative claims data) and 
confidentiality requirements 
Study Design Rationale and description of study design, to include: (i) rationale for choice of study design; (ii) 
concurrence with good practice guidelines; (iii) treatment comparators; (vi) timeframe; (v) 
statistical and analysis plan; (vi) data sources; (vii) statistical hypotheses ; (viii) description of 
statistical methods; (ix) sample size; (x) procedures to minimize bias; (xi) quality assurance; (xii) 
confidentiality; (xiii) data handling; and (xiv) reporting. 
Budget A detailed budget and a commitment to underwriting the evaluation. 
Interim 
Reporting 
Proposed schedule for interim reporting of study implementation and progress. 
 
Final Report Proposed submission data for final report and proposed report outline. 
 
 
 
Table 2: GFE: Questions a Formulary Committee Should Ask 
Section Question 
Objectives Has the protocol provided a summary of the study objectives?  Does the protocol abstract 
provide a summary of (i) population targeted; (ii) comparators; (iii) timeframe; (iv) study design; 
(v) data sources; (vi) endpoints; and (vii) reporting format?  
Context Has the protocol provided a systematic review to establish the context for the claims to be 
validated and the contribution this validation may have to an overall assessment of comparative 
treatment benefits and harms in the population targeted and indication for the product? 
Target 
Population 
Has the protocol provided a rationale for the population to be targeted, to include (i) 
demographic characteristics; (ii) clinical status; (iii) disease stage; (iv) co-morbidities? 
Claims Has the protocol provided a summary of the modeled claims for cost-effectiveness to be 
evaluated? Has the protocol identified claims for (i) clinical benefits; (ii) adverse events and 
safety; (iii) resource utilization; (iv) direct medical costs; and (v) cost-effectiveness? 
Study Design Has the protocol provided a rationale for the study design (e.g., prospective effectiveness trial, 
cohort/ observational study) Were alternative study designs proposed? Were risks of bias and 
other limitations described? 
Implementation 
and Reporting 
Has the protocol given a timetable for interim and final reporting of results? 
 
